Reardon Claudia L, Creado Shane
a Department of Psychiatry , University of Wisconsin School of Medicine and Public Health , Madison , WI , USA.
b Counseling and Consultation Services , University Health Services , Madison , WI , USA.
Phys Sportsmed. 2016 Nov;44(4):397-402. doi: 10.1080/00913847.2016.1216719. Epub 2016 Aug 2.
When prescribing psychiatric medications to athletes, it is important to consider issues that are especially important for this population, including side effects, safety concerns, and anti-doping policies. Only one report, from 2000, describes the prescribing preferences of psychiatrists who work with athletes. This manuscript aims to update the findings from that report, so as to help inform prescribing practices of primary care physicians, psychiatrists, and other clinicians who work with athletes.
Physician members of the International Society for Sports Psychiatry (ISSP) were sent an email invitation in 2016 to complete an anonymous web-based survey on psychiatric medication prescribing preferences in working with athletes with a variety of mental health conditions.
Forty of 100 (40%) members of the ISSP who identified as physicians and who were emailed the survey ultimately completed it. Top choices of psychiatric medications for athletes across categories assessed included: bupropion for depression without anxiety and without bipolar spectrum disorder; escitalopram for generalized anxiety disorder; melatonin for insomnia; atomoxetine for attention-deficit/hyperactivity disorder; lamotrigine for bipolar spectrum disorders; and aripiprazole for psychotic disorders.
Prescribers of psychiatric medications for athletes tended to favor medications that are relatively more energizing and less likely to cause sedation, weight gain, cardiac side effects, and tremor. Additionally, prescribing preferences for athletes diverged from many of the prescribing trends seen for patients within the general population, in keeping with the assumption that different factors are considered when prescribing for athletes versus for the general population.
在给运动员开具精神科药物时,考虑对该人群尤为重要的问题很重要,这些问题包括副作用、安全问题和反兴奋剂政策。仅有一份2000年的报告描述了治疗运动员的精神科医生的处方偏好。本手稿旨在更新该报告的研究结果,以帮助为初级保健医生、精神科医生以及其他治疗运动员的临床医生的处方实践提供参考。
2016年,向国际运动精神病学协会(ISSP)的医生会员发送了一封电子邮件邀请,邀请他们完成一项基于网络的匿名调查,内容是关于在治疗患有各种心理健康状况的运动员时的精神科药物处方偏好。
100名自认为是医生并收到调查问卷电子邮件的ISSP成员中,有40名(40%)最终完成了调查。在评估的各类别中,运动员精神科药物的首选包括:用于无焦虑且无双相谱系障碍的抑郁症的安非他酮;用于广泛性焦虑症的艾司西酞普兰;用于失眠的褪黑素;用于注意力缺陷多动障碍的托莫西汀;用于双相谱系障碍的拉莫三嗪;以及用于精神障碍的阿立哌唑。
为运动员开具精神科药物的处方者倾向于选择相对更具兴奋性且不太可能引起镇静、体重增加、心脏副作用和震颤的药物。此外,与普通人群患者的许多处方趋势不同,运动员的处方偏好有所不同,这与为运动员与普通人群开处方时考虑不同因素这一假设相符。